MA40662B1 - Anticorps contre tigit - Google Patents

Anticorps contre tigit

Info

Publication number
MA40662B1
MA40662B1 MA40662A MA40662A MA40662B1 MA 40662 B1 MA40662 B1 MA 40662B1 MA 40662 A MA40662 A MA 40662A MA 40662 A MA40662 A MA 40662A MA 40662 B1 MA40662 B1 MA 40662B1
Authority
MA
Morocco
Prior art keywords
antibodies
antibodies against
treatment
against tigit
fragments
Prior art date
Application number
MA40662A
Other languages
English (en)
Other versions
MA40662A1 (fr
Inventor
Mohan Srinivasan
Indrani Chakraborty
Mark F Maurer
Tseng-Hui Timothy Chen
Brigitte Devaux
Susan H Julien
Paul O Sheppard
Daniel F Ardourel
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA40662A1 publication Critical patent/MA40662A1/fr
Publication of MA40662B1 publication Critical patent/MA40662B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps, ou des fragments liant l'antigène de ceux-ci, qui se lient à un tigit (immunorécepteur de cellule t avec des domaines d'ig et d'itim) humain, ainsi que des utilisations de ces anticorps ou fragments dans des applications thérapeutiques, par exemple dans le traitement du cancer ou d'une infection virale chronique. Ce procédé de traitement comprend un traitement combiné avec des inhibiteurs d'autres interactions avec des récepteurs immunomodulateurs, comme une i
MA40662A 2014-12-23 2015-12-22 Anticorps contre tigit MA40662B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096267P 2014-12-23 2014-12-23
PCT/US2015/067332 WO2016106302A1 (fr) 2014-12-23 2015-12-22 Anticorps contre tigit

Publications (2)

Publication Number Publication Date
MA40662A1 MA40662A1 (fr) 2020-06-30
MA40662B1 true MA40662B1 (fr) 2020-12-31

Family

ID=55168435

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40662A MA40662B1 (fr) 2014-12-23 2015-12-22 Anticorps contre tigit

Country Status (23)

Country Link
US (3) US10189902B2 (fr)
EP (2) EP3237448A1 (fr)
JP (6) JP6180663B2 (fr)
KR (1) KR102644115B1 (fr)
CN (3) CN110256558B (fr)
AR (1) AR103268A1 (fr)
AU (2) AU2015369683C1 (fr)
BR (1) BR112017013385A2 (fr)
CL (1) CL2017001660A1 (fr)
CO (1) CO2017006989A2 (fr)
EA (1) EA039219B1 (fr)
IL (2) IL253013B (fr)
MA (1) MA40662B1 (fr)
MX (2) MX389267B (fr)
MY (1) MY187045A (fr)
PE (1) PE20171244A1 (fr)
PH (2) PH12022550771A1 (fr)
SG (2) SG10202006538TA (fr)
TN (1) TN2017000267A1 (fr)
TW (1) TWI708786B (fr)
UY (1) UY36471A (fr)
WO (1) WO2016106302A1 (fr)
ZA (2) ZA201704981B (fr)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN108290936B (zh) 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
PT3356413T (pt) * 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018024162A1 (fr) * 2016-08-03 2018-02-08 Sunshine Lake Pharma Co., Ltd. Protéine de fusion glp-1 comprenant une partie fc d'immunoglobuline mutée
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (fr) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec un tigit humain ou chimérique
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
MX2019006072A (es) * 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
WO2018102746A1 (fr) * 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Molécules de liaison à l'antigène destinées à la tigit
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
WO2018128939A1 (fr) * 2017-01-05 2018-07-12 Gensun Biopharma Inc. Antagonistes de régulateur de point de contrôle
EP3589313A4 (fr) * 2017-02-28 2021-05-19 Seagen Inc. Anticorps anti-tigit
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
JOP20190203A1 (ar) * 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
EP4286009A3 (fr) 2017-04-21 2024-04-03 Sillajen, Inc. Polythérapie à base de virus de la vaccine oncolytique et d'inhibiteur de point de contrôle
EP3615070A1 (fr) * 2017-04-26 2020-03-04 Bristol-Myers Squibb Company Procédés de production d'anticorps qui réduisent au minimum la réduction de liaison disulfure
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102770786B1 (ko) * 2017-05-02 2025-02-20 머크 샤프 앤드 돔 엘엘씨 항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
JP7348072B2 (ja) * 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
WO2018229163A1 (fr) 2017-06-14 2018-12-20 King's College London Méthodes d'activation des lymphocytes t v delta 2 négatifs gamma delta
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
WO2019023504A1 (fr) 2017-07-27 2019-01-31 Iteos Therapeutics Sa Anticorps anti-tigit
BE1025333B1 (fr) * 2017-07-27 2019-01-23 Iteos Therapeutics S.A. Anticorps anti-tigit
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CN109425736B (zh) * 2017-08-25 2021-04-09 北京百普赛斯生物科技股份有限公司 一种检测pd-1抗体血药浓度的方法及试剂盒
EP3679364A1 (fr) 2017-09-07 2020-07-15 Bristol-Myers Squibb Company Procédé de détermination de pureté par électrophorèse capillaire
EP3681908A1 (fr) * 2017-09-13 2020-07-22 Teneobio, Inc. Anticorps à chaîne lourde se liant à des exoenzymes
JP7317272B2 (ja) * 2017-09-29 2023-07-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
US20190099506A1 (en) * 2017-10-02 2019-04-04 Bristol-Myers Squibb Company Methods and compositions for deuterated biologics
BR112020007002A2 (pt) * 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
JP2021506827A (ja) * 2017-12-15 2021-02-22 シルバーバック セラピューティックス インコーポレイテッド 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
EP3728314A1 (fr) 2017-12-19 2020-10-28 Kymab Limited Anticorps bispécifique pour icos et pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN117050184A (zh) * 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
TWI877769B (zh) 2017-12-30 2025-03-21 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
AU2019207296A1 (en) * 2018-01-15 2020-07-16 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
KR102224556B1 (ko) 2018-02-06 2021-03-09 아이-맵 바이오파마 유에스 리미티드 Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
CN111836831A (zh) * 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
EP3768715A1 (fr) * 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Anticorps contre mica et/ou micb et leurs utilisations
MA52175A (fr) 2018-03-26 2021-02-17 Regeneron Pharma Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène
WO2019195126A1 (fr) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anticorps anti-trem-1 et utilisations associées
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
KR20210016448A (ko) 2018-06-01 2021-02-15 컴퓨젠 엘티디. 항-pvrig/항-tigit 이중특이적 항체 및 사용 방법
US10597453B2 (en) * 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
WO2020020281A1 (fr) 2018-07-25 2020-01-30 信达生物制药(苏州)有限公司 Anticorps anti-tigit et ses utilisations
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
WO2020036987A1 (fr) 2018-08-13 2020-02-20 Signablok, Inc. Peptides et compositions pour traitement et imagerie ciblés
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
WO2020069382A1 (fr) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Molécules de liaison anti-cd137 comprenant des domaines fc modifiés et leurs utilisations thérapeutiques
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
WO2020081408A1 (fr) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-rsv et leurs procédés d'utilisation
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
CA3118964A1 (fr) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Schema posologique d'anticorps anti-tigit pour le traitement du cancer
EP3876990A4 (fr) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
US12312401B2 (en) 2019-01-07 2025-05-27 Iteos Belguim Sa Anti-TIGIT antibodies
CN113396162B (zh) * 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
SG11202108398YA (en) * 2019-02-01 2021-08-30 Novarock Biotherapeutics Ltd Anti-claudin 18 antibodies and methods of use thereof
KR20210126638A (ko) * 2019-02-06 2021-10-20 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem1 항체 및 관련 방법
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
JP2022530496A (ja) * 2019-04-26 2022-06-29 ウーシー バイオロジクス アイルランド リミテッド Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243570A1 (fr) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Signature de localisation cellulaire et polythérapie
KR102332847B1 (ko) * 2019-06-13 2021-12-01 주식회사 녹십자 Tigit에 대한 항체 및 이의 용도
EP3986936A4 (fr) * 2019-06-21 2023-03-15 Single Cell Technology, Inc. Anticorps anti-tigit
CN114340735B (zh) 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
CA3146986A1 (fr) * 2019-07-15 2021-01-21 Shanghai Junshi Biosciences Co., Ltd. Anticorps anti-tigit et leur application
WO2021023117A1 (fr) * 2019-08-02 2021-02-11 康方药业有限公司 Anticorps anti-ctla4-anti-pd-1 bispécifique et ses utilisations
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
CA3149719A1 (fr) * 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Anticorps se liant a vista a un ph acide
US11667709B2 (en) 2019-09-24 2023-06-06 Industrial Technology Research Institute Anti-TIGIT antibodies and methods of use
US20220340660A1 (en) * 2019-10-01 2022-10-27 Merck Sharp & Dohme Corp. Biomarkers for anti-tigit antibody treatment
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
EP4041392A1 (fr) * 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Anticorps dirigés contre le récepteur du poliovirus (pvr) et leurs utilisations
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
CN114728171A (zh) * 2019-11-05 2022-07-08 默克专利有限公司 抗tigit抗体及其应用
WO2021093849A1 (fr) * 2019-11-14 2021-05-20 Wuxi Biologics (Shanghai) Co., Ltd. Nouvel anticorps dirigé contre tigit
PH12022551278A1 (en) * 2019-11-25 2023-11-20 Akeso Biopharma Inc Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
WO2021139776A1 (fr) * 2020-01-10 2021-07-15 Shanghai Henlius Biotech, Inc. Anticorps anti-tigit, anticorps multispécifiques les comprenant, et leurs procédés d'utilisation
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN115052622B (zh) * 2020-01-21 2026-03-06 夏尔巴生物技术(杭州)有限公司 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
CN115335406B (zh) 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
EP4114863A4 (fr) * 2020-03-05 2024-04-24 Merck Sharp & Dohme LLC Méthodes de traitement du cancer ou d'une infection faisant appel à une association d'un anticorps anti-pd-1, d'un anticorps anti-ctla4 et d'un anticorps anti-tigit
CA3170025A1 (fr) 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Proteine de liaison a pvgrig et ses utilisations medicales
CN113563470B (zh) * 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
CN115943312A (zh) 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CN115803343A (zh) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 多特异性抗体及其应用
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
KR20230024368A (ko) 2020-06-18 2023-02-20 제넨테크, 인크. 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
CN111718415B (zh) * 2020-07-03 2021-02-23 上海洛启生物医药技术有限公司 一种抗tigit纳米抗体及其应用
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
WO2022020353A2 (fr) * 2020-07-20 2022-01-27 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour le traitement et la prévention d'une infection par un coronavirus
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022063100A1 (fr) 2020-09-22 2022-03-31 南京圣和药业股份有限公司 Anticorps anti-tigit et anticorps double et leur application
WO2022069940A1 (fr) 2020-09-30 2022-04-07 Compugen Ltd. Polythérapie avec des formulations d'anticorps anti-pvrig, des anticorps anti-tigit et des anticorps anti-pd-1
US20240002504A1 (en) * 2020-10-26 2024-01-04 Akeso Biopharma, Inc. Anti-tigit antibody, and pharmaceutical composition and use thereof
WO2022098972A1 (fr) 2020-11-08 2022-05-12 Seagen Inc. Polythérapie à base d'un conjugué anticorps-médicament avec un nhibiteur de cellules immunitaires
US11028172B1 (en) * 2020-11-10 2021-06-08 Lepu Biopharma Co., Ltd. Anti-TIGIT antibodies and uses thereof
WO2022105872A1 (fr) 2020-11-23 2022-05-27 广东菲鹏制药股份有限公司 Anticorps anti-tigit ou fragment de liaison à l'antigène de celui-ci
WO2022112198A1 (fr) 2020-11-24 2022-06-02 Worldwide Innovative Network Procédé de sélection des thérapies optimales par points de contrôle immunitaire
CN114539418A (zh) * 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 双特异性抗体及其用途
WO2022111612A1 (fr) * 2020-11-26 2022-06-02 信达生物制药(苏州)有限公司 Préparation comprenant un anticorps bispécifique anti-tigit/pd-1, son procédé de préparation et son utilisation
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
CN112538108B (zh) * 2020-12-24 2022-06-28 郑州大学 高亲和pvr突变体
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
CN116897202A (zh) * 2021-02-24 2023-10-17 科济生物医药（上海）有限公司 Tigit工程化细胞及其组合物
EP4314068A1 (fr) 2021-04-02 2024-02-07 The Regents Of The University Of California Anticorps dirigés contre un cdcp1 clivé et leurs utilisations
EP4320160A1 (fr) 2021-04-09 2024-02-14 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-tigit
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (fr) 2021-04-09 2024-02-14 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
MX2023013335A (es) 2021-05-10 2024-01-16 Medimabbio Inc Anticuerpos anti-tigit y usos de los mismos.
CN115466327B (zh) * 2021-06-10 2025-07-08 北京天广实生物技术股份有限公司 结合tigit的抗体及其用途
IL310217A (en) * 2021-07-23 2024-03-01 Akeso Biopharma Inc Pharmaceutical composition and use
WO2023010094A2 (fr) 2021-07-28 2023-02-02 Genentech, Inc. Méthodes et compositions pour le traitement du cancer
WO2023020625A1 (fr) * 2021-08-20 2023-02-23 中山康方生物医药有限公司 PROTÉINE DE FUSION CONTENANT UN ANTICORPS ANTI-TIGIT ET UN TGF-βR, ET COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE
EP4403574A4 (fr) 2021-09-15 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co Ltd Protéine se liant de manière spécifique à pd-1 et son utilisation pharmaceutique
EP4403573A4 (fr) 2021-09-15 2024-12-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Composition pharmaceutique comprenant un anticorps bispécifique anti-pvrig/tigit
WO2023056403A1 (fr) 2021-09-30 2023-04-06 Genentech, Inc. Méthodes de traitement de cancers hématologiques au moyen d'anticorps anti-tigit, d'anticorps anti-cd38 et d'antagonistes de liaison à l'axe pd-1
WO2023064958A1 (fr) 2021-10-15 2023-04-20 Compugen Ltd. Polythérapie avec des formulations d'anticorps anti-pvrig, d'anticorps anti-tigit et d'anticorps anti-pd-1
US20240425588A1 (en) * 2021-11-10 2024-12-26 Apeximmune Therapeutics Inc. Anti-tigit constructs and uses thereof
WO2023108609A1 (fr) * 2021-12-17 2023-06-22 Shanghai Nigene Biological Science And Technology Co., Ltd. Anticorps anti-tigit et leurs utilisations
WO2023149978A1 (fr) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Biomarqueurs du cancer et traitements du cancer
JP2025508076A (ja) 2022-03-08 2025-03-21 アレンティス・セラピューティクス・アクチェンゲゼルシャフト Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
WO2023178192A1 (fr) 2022-03-15 2023-09-21 Compugen Ltd. Anticorps antagonistes de l'il-18bp et leur utilisation en monothérapie et polythérapie dans le traitement du cancer
WO2023178329A1 (fr) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Procédés d'isolement de polypeptides
AU2023264591A1 (en) 2022-05-02 2024-11-07 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
KR20250022071A (ko) 2022-06-02 2025-02-14 브리스톨-마이어스 스큅 컴퍼니 항체 조성물 및 이의 이용 방법
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
US20260035460A1 (en) 2022-07-28 2026-02-05 Adeboye Henry ADEWOYE, MD Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
CN116143923B (zh) * 2022-12-30 2025-11-11 合肥天港免疫药物有限公司 高亲和力tigit抗体及其应用
EP4658687A1 (fr) 2023-01-31 2025-12-10 University of Rochester Thérapie de blocage de point de contrôle immunitaire pour le traitement d'infections par staphylococcus aureus
WO2024191807A1 (fr) 2023-03-10 2024-09-19 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-tigit
KR20250156744A (ko) 2023-03-15 2025-11-03 상하이 맙젠 바이오텍 리미티드 Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도
WO2024196952A1 (fr) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Évaluation de sous-type de tumeur pour une thérapie anticancéreuse
CN118725130A (zh) * 2023-03-21 2024-10-01 上海赛金生物医药有限公司 抗ctla-4/抗tigit双特异性抗体及其应用
WO2024200820A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Procédé de synthèse de nanoparticule lipidique ciblée et ses utilisations
EP4687991A1 (fr) 2023-03-30 2026-02-11 Ose Immunotherapeutics Nanoparticule à base de lipide ciblant des cellules immunitaires activées pour l'expression d'une molécule d'amélioration de cellule immunitaire et son utilisation
WO2024249894A2 (fr) * 2023-06-02 2024-12-05 Arcus Biosciences, Inc. Biomarqueurs pour prédire l'efficacité d'un traitement du cancer
EP4724493A1 (fr) * 2023-06-06 2026-04-15 WuXi Biologics Ireland Limited Anticorps anti-tigit et leurs utilisations
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025002151A1 (fr) * 2023-06-27 2025-01-02 正大天晴药业集团股份有限公司 Anticorps anti-tigit et leur utilisation
WO2025038763A1 (fr) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Procédé de chromatographie en flux continu d'hydroxyapatite céramique
WO2025068452A1 (fr) 2023-09-29 2025-04-03 Negio Therapeutics Dérivés du guanfacine et leur utilisation dans le traitement du cancer
WO2025068461A1 (fr) 2023-09-29 2025-04-03 Negio Therapeutics Dérivés de guanfacine et leur utilisation dans le traitement du cancer
WO2025132831A1 (fr) 2023-12-19 2025-06-26 Universite D'aix-Marseille Dérivés de n-hétéroaryle et leurs utilisations pour le traitement du cancer
WO2025145207A1 (fr) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Polythérapie d'inhibiteur de kras et d'agent de déplétion des treg
KR102872375B1 (ko) * 2024-01-24 2025-10-24 메디맵바이오 주식회사 Tigit에 특이적으로 결합하는 항-tigit 항체, 상기 항체 및 인터루킨-10를 포함하는 융합 단백질 및 이들의 용도
WO2025242835A1 (fr) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molécules comprenant des lieurs de masquage et leurs utilisations pour le traitement du cancer
WO2025242836A1 (fr) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molécules comprenant des lieurs de masquage et leurs utilisations pour le traitement de maladies et de troubles auto-immuns ou inflammatoires
WO2025262250A1 (fr) 2024-06-20 2025-12-26 Negio Therapeutics Dérivés de guanfacine et leurs utilisations
WO2026068705A1 (fr) 2024-09-26 2026-04-02 Ose Immunotherapeutics Nanoparticules à base de lipides comprenant des domaines fc non glycosylés et leurs utilisations

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (fr) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. Methode de production d'anticorps avec activite adcc accrue
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
EP1212422B1 (fr) 1999-08-24 2007-02-21 Medarex, Inc. Anticorps contre l'antigene ctla-4 humain et utilisation
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
CA2430013C (fr) 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
CA2463879C (fr) 2001-10-25 2012-12-04 Genentech, Inc. Compositions de glycoproteine
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
EP1553975B8 (fr) 2002-09-27 2023-04-12 Xencor, Inc. Variants fc optimises et methodes destinees a leur generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (fr) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP1737890A2 (fr) 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20090145493A1 (en) 2004-11-23 2009-06-11 Pip Co., Ltd. Built-in wall water service box
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
EP1891107B1 (fr) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions et procedes permettant de moduler des reponses immunitaires
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036642A2 (fr) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
WO2009014708A2 (fr) 2007-07-23 2009-01-29 Cell Genesys, Inc. Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
DE102007036200A1 (de) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
ES2526355T3 (es) 2007-10-01 2015-01-09 Bristol-Myers Squibb Company Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos
CL2008003527A1 (es) 2007-11-30 2009-10-09 Medarex Inc Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
CL2008003526A1 (es) 2007-11-30 2010-01-11 Medarex Inc Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
EP2229410A4 (fr) 2007-12-05 2012-07-04 Massachusetts Inst Technology Mutants d'immunoglobuline aglycosylée
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
CN103372215B (zh) 2008-01-03 2016-03-09 艾克斯-马赛大学 抗hiv治疗期间使用的组合物和方法
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
WO2009127691A1 (fr) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
WO2009135181A2 (fr) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Procédé et compositions pour préparer des anticorps et des dérivés d'anticorps avec une fucosylation centrale réduite
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010077643A1 (fr) 2008-12-08 2010-07-08 Tegopharm Corporation Ligands de masquage pour inhibition réversible de composés polyvalents
EP3255060A1 (fr) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (fr) 2009-10-28 2016-10-05 Newlink Genetics Corporation Dérivés imidazole comme inhibiteurs de l'ido
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
EP2542256B1 (fr) 2010-03-04 2019-05-22 MacroGenics, Inc. Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
US8822642B2 (en) 2010-06-09 2014-09-02 Zymogenetics, Inc. Dimeric fusion proteins and related compositions and methods
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012087928A2 (fr) 2010-12-20 2012-06-28 The Rockefeller University Modulation d'anticorps agonistes anti-tnfr
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
EP3415528B1 (fr) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Protéines de fusion fc comprenant de nouveaux lieurs et arrangements
NO2694640T3 (fr) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
US20130149300A1 (en) 2011-09-27 2013-06-13 Icon Genetics Gmbh MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
PT2793943T (pt) 2011-12-19 2018-11-13 Univ Rockefeller Polipéptidos anti-inflamatórios não siliados
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
SG11201405059XA (en) * 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
ES2984405T3 (es) 2012-09-13 2024-10-29 Bristol Myers Squibb Co Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
EP3508215A3 (fr) * 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Amélioration de l'activité anticancéreuse de protéines de fusion fc immunomodulatrices
HK1210964A1 (en) 2012-12-04 2016-05-13 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
GB201308658D0 (en) 2013-05-14 2013-06-26 Isis Innovation Antibodies
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
KR20250024106A (ko) 2013-08-22 2025-02-18 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
EP3119913B1 (fr) * 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique
EP3169363A4 (fr) 2014-07-16 2018-02-21 F. Hoffmann-La Roche AG Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
PE20181046A1 (es) 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso

Also Published As

Publication number Publication date
US20210324072A1 (en) 2021-10-21
US20160176963A1 (en) 2016-06-23
TW201629102A (zh) 2016-08-16
CL2017001660A1 (es) 2018-03-23
CN116731176A (zh) 2023-09-12
TWI708786B (zh) 2020-11-01
IL285287B1 (en) 2023-03-01
IL253013B (en) 2021-08-31
JP2025128184A (ja) 2025-09-02
EP3237448A1 (fr) 2017-11-01
AR103268A1 (es) 2017-04-26
JP2017520512A (ja) 2017-07-27
ZA201704981B (en) 2019-08-28
JP2020062026A (ja) 2020-04-23
EA039219B1 (ru) 2021-12-20
CN107207594A (zh) 2017-09-26
KR20170099966A (ko) 2017-09-01
WO2016106302A1 (fr) 2016-06-30
JP2018035138A (ja) 2018-03-08
UY36471A (es) 2016-06-30
EA201791171A1 (ru) 2017-11-30
IL253013A0 (en) 2017-08-31
AU2015369683C1 (en) 2024-06-20
MA40662A1 (fr) 2020-06-30
PE20171244A1 (es) 2017-08-24
AU2021201231B2 (en) 2024-02-22
MX389267B (es) 2025-03-20
MX2021012074A (es) 2021-11-03
EP4249066A3 (fr) 2023-11-22
SG10202006538TA (en) 2020-08-28
US11008390B2 (en) 2021-05-18
IL285287A (en) 2021-09-30
CN107207594B (zh) 2019-05-07
BR112017013385A2 (pt) 2018-02-06
US20190112375A1 (en) 2019-04-18
EP4249066A2 (fr) 2023-09-27
PH12022550771A1 (en) 2023-02-27
JP2023139046A (ja) 2023-10-03
CN110256558A (zh) 2019-09-20
PH12017501166B1 (en) 2017-12-11
CA2971732A1 (fr) 2016-06-30
CN110256558B (zh) 2023-07-04
KR102644115B1 (ko) 2024-03-05
IL285287B2 (en) 2023-07-01
CO2017006989A2 (es) 2018-01-05
SG11201705063VA (en) 2017-07-28
US12060421B2 (en) 2024-08-13
MX2017007744A (es) 2017-09-05
AU2021201231A1 (en) 2021-03-11
AU2015369683B2 (en) 2020-12-10
JP2021177759A (ja) 2021-11-18
ZA201806307B (en) 2022-03-30
AU2015369683A1 (en) 2017-08-10
TN2017000267A1 (en) 2018-10-19
JP6180663B2 (ja) 2017-08-16
JP6633032B2 (ja) 2020-01-22
MY187045A (en) 2021-08-27
PH12017501166A1 (en) 2017-12-11
US10189902B2 (en) 2019-01-29
WO2016106302A9 (fr) 2017-06-22

Similar Documents

Publication Publication Date Title
MA40662B1 (fr) Anticorps contre tigit
MX375800B (es) Anticuerpos humanizados contra cd269 (bcma).
BR112018072211A2 (pt) anticorpos anti tl1a e utilizações dos mesmos
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d'utilisation
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EP4464341A3 (fr) Ligands psma pour imagerie et endoradiothérapie
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
EA201691482A1 (ru) Человеческие антитела к pd-1
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
HK1255039A1 (zh) 对pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA40913A (fr) Conjugués anticorps-médicament
JOP20200157B1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
MX2016014210A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
MA38161A1 (fr) Anticorps anti-bmp-6
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
JOP20180121A1 (ar) أجسام مضادة ضد عامل التخثر xi
BR112017025496A2 (pt) Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
MA38296B2 (fr) Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations